Praxis Precision Medicines to Participate in Upcoming Fireside Chat

About this update from Praxis Precision Medicines, Inc.

BOSTON , Nov. 20, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines , Inc. (NASDAQ: PRAX ), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that HCWainwright analyst Doug Tsao will host an expert call on Deep Dive into Praxis’ Ulixacaltamide Data with statistician Prof. Chuck McCullogh , University of California, San Francisco on November 24, 2025 at 1:00pm EST which will be joined by Marcio Souza , Praxis’ CEO. The registration link can be found here . About Praxis Praxis Precision Medicines is a clinical-stage biopharmaceutical company translating insights from genetic epilepsies into the development of therapies for CNS disorders characterized by neuronal excitation-inhibition imbalance. Praxis is applying genetic insights to the discovery and development of therapies for rare and more prevalent neurological disorders through our proprietary small molecule platform, Cerebrum™, and antisense oligonucleotide (ASO) platform, Solidus™, using our understanding of shared biological targets and circuits in the brain. Praxis has established a diversified, multimodal CNS portfolio including multiple programs across epilepsy and movement disorders, with four clinical-stage product candidates. For more information, please visit www.praxismedicines.com and follow us on Facebook , Instagram , LinkedIn and Twitter/X . Investor Contact: Praxis Precision Medicines [email protected] 857-702-9452 Media Contact: Dan Ferry Life Science Advisors [email protected] 617-430-7576 Source: Praxis Precision Medicines, Inc.

View stock analysis, news, and events for Praxis Precision Medicines, Inc.